Skip to main content

RA Capital Management — Portfolio, Page 3

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

453
Companies
$44.2B
Total invested
$123.1M
Avg. check
16
Industries
Biotechnology 22Health Care 13Medical 11Therapeutics 11Biopharma 8Pharmaceutical 8+10 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 4972 of 453
Mineralys Therapeutics
June 2026

Mineralys Therapeutics is a clinical-stage biopharmaceutical company committed to developing therapy for the treatment of hypertension.

Biopharma · Radnor$500.0M Post-IPO Debt
Pyxis Oncology
June 2026

Pyxis Oncology is a biotechnology firm that develops antibody therapeutics intended to promote the body's immune response to cancer.

Biotechnology · Boston$50.0M Post-IPO Equity
Blueprint Medicines
June 2022

Blueprint Medicines develops precision therapies for genomically defined cancers and rare diseases.

Bioinformatics · Cambridge$1.3B Post-IPO Equity
Black Diamond Therapeutics
June 2023

Black Diamond Therapeutics is a medical company focused on analyzing genetically defined cancers.

Biotechnology · Cambridge$75.0M Post-IPO Equity
Cerebral Therapeutics
June 2022

Cerebral Therapeutics is a clinical-stage pharmaceutical company.

Biotechnology · Aurora$40.0M Series C
Medicenna Therapeutics
June 2026

Medicenna is a clinical stage, privately held, immuno-oncology company.

Biotechnology · Toronto$4.4M Post-IPO Equity
ALX Oncology
June 2026

ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.

Biopharma · San Francisco$10.0M Post-IPO Debt
Frontier Medicines
June 2024

Frontier Medicines is a biopharmaceutical company that develops a chemoproteomics platform to accelerate the development of medicines.

Biopharma · San Francisco$20.0M Series C
Ollin Biosciences
June 2026

Ollin Biosciences develops ophthalmic therapies focused on treating serious vision-threatening diseases.

Biopharma · Austin$330.0M Series B
Taysha Gene Therapies
June 2026

Taysha Gene Therapies develops treatments to eradicate severe and life-threatening monogenic diseases of the central nervous system.

Biotechnology · Dallas$200.0M Post-IPO Equity
Helus Pharma
June 2026

Helus Pharma is a biopharmaceutical company that develops psychedelic therapeutics for mental health conditions.

Biotechnology · Toronto$50.0M Post-IPO Equity
NorthLinks Bio
June 2026

NorthLinks Bio is a clinical-stage biopharmaceutical company developing HEX17.

Biotechnology · Boston$34.0M Venture - Series Unknown
Aurinia Pharmaceuticals
June 2026

Aurinia develops and commercializes therapies to treat targeted patient populations suffering from serious auto-immune diseases.

Biopharma · Victoria$3.1M Post-IPO Equity
Contraline
June 2026

Contraline is a clinical-stage biotechnology company that develops male contraceptive solutions.

Biotechnology · Charlottesville$92.5M Series B
Aeglea BioTherapeutics
June 2023

Aeglea BioTherapeutics is a clinical-stage biotechnology company that develops enzyme therapies for rare metabolic diseases.

Biotechnology · Austin$210.0M Post-IPO Equity
Scribe Therapeutics
June 2026

Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR molecules.

Biotechnology · Alameda$25.0M Grant
Memento Medicines
June 2026

Memento Medicines is a biotech developing bispecific antibody therapies for eye diseases.

Biotechnology · Chester$93.0M Series A
Legend Biotech
June 2026

Legend Biotech is a biopharmaceutical company that develops and commercializes novel cell therapies for oncology.

Biotechnology · Piscataway$226.0M Post-IPO Equity
Moderna
June 2026

Moderna Therapeutics is a biotechnology company that develops medicines and vaccines based on messenger RNA (mRNA) technology.

Biotechnology · Cambridge$50.0M Grant
Parabilis Medicines
June 2026

Parabilis Medicines is a Grupo Bugio is a biopharmaceutical firm that specializes in creating medicines.

Biopharma · Cambridge$75.0M Post-IPO Equity
CervoMed
June 2026

CervoMed a clinical-stage firm focused on discovering therapies for brain degenerative illnesses.

Health Care · Boston$10.5M Post-IPO Equity
SonoThera
June 2026

SonoThera develops ultrasound-based technologies for delivering genetic therapies to targeted tissues.

Biopharma · South San Francisco$125.0M Series B
SAB Biotherapeutics
March 2026

SAB Biotherapeutics is a clinical-stage biopharmaceutical development company.

Biotechnology · Sioux Falls$85.0M Post Ipo Equity
Equillium
March 2026

Equillium is a biotechnology company that develops products for autoimmune and inflammatory disorders with an unmet medical need.

Biopharma · La Jolla$35.0M Post Ipo Equity

Where RA Capital Management invests

Biotechnology22
Health Care13
Medical11
Therapeutics11
Biopharma8
Pharmaceutical8

About RA Capital Management's portfolio

How many companies has RA Capital Management invested in?

RA Capital Management has invested in 453 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does RA Capital Management invest in?

RA Capital Management's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Biopharma. The firm invests across 16 different industry categories.

What is RA Capital Management's largest investment?

Among tracked funding rounds, Blueprint Medicines received $1.3B in a Post-IPO Equity round. RA Capital Management's total known invested capital is $44.2B.

What is the average investment size for RA Capital Management?

RA Capital Management's average investment size is $123.1M across its portfolio of 453 companies.

What are RA Capital Management's most recent investments?

Recent RA Capital Management portfolio additions include Mineralys Therapeutics, Pyxis Oncology, Blueprint Medicines, Black Diamond Therapeutics, Cerebral Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 453 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →